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Abstract 
The delivery of genetic materials into cells to elicit cellular response has been greatly studied 
by biomaterials scientists globally. Many materials such as lipids, peptides, viruses, 
synthetically modified cationic polymers and certain inorganic nanomaterials could be used 
to complex the negatively charged plasmids and deliver the formed package into cells. The 
recent literature on the delivery of genetic material utilising inorganic nanoparticles is 
carefully examined in this review. We pick out the most relevant references and concisely 
summarise the findings with illustrated examples. We further propose alternative approaches 





Recent advances in gene therapy have paved the way towards the effective treatment 
of human diseases originating from defective genes, such as cancers, Parkinson’s disease, 
cystic fibrosis and muscular degeneration.
1-4
 Effective and specific in vivo delivery of 
therapeutic genetic materials into a cell, however, remains as a major challenge and is 
generally considered as the crucial factor in determining the potency of a particular gene 
therapy.
5-8
 In spite of their high efficiency and common usage in gene delivery, viral vectors 
inherit fundamental drawbacks (immunological problems, insertional mutagenesis and 
limitations in the size of the carried therapeutic genes) that need to be addressed before any 
human clinical trials can be safely conducted.
7
 Polymeric, lipid and peptide carriers have 
been extensively studied in recent years.
9-17
 Functional inorganic nanomaterials recently 
emerged as robust and versatile nanoscaffolds for effective gene delivery applications.
5, 6
 
Significantly, without the limitations associated with viral vectors, inorganic nanomaterials 
further offer an appealing set of properties for practical applications, including scalability in 
synthesis, facile functionalization, chemical and thermal stability. These properties are 
important for sterilization, low inherent toxicity (especially for gold, iron oxide and silica 
nanoparticles), availability in a wide range of size and shape, and the possibility of real-time 
tracking by various spectroscopic techniques.  
 
Concept 
In general, an effective nanocarrier needs to provide robust protection of nucleic acid 
from degradation by nucleases, efficient cell entry through the cell membrane, and release of 
the nucleic acid in its functional form within the nucleus (Scheme 1).
18
 This was typically 
achieved by tailoring the size and the surface functionalities (charges, hydrophobicity, and 
3 
 
targeting groups) of the nanomaterials employed in gene delivery. Owing to the phosphate 
backbone, DNA and small interfering RNA (siRNA) are negatively charged moieties. Hence, 
nanoscaffolds with positively charged surface groups can noncovalently conjugate to DNA or 
RNA via electrostatic attractions, as have been widely employed in various nanoscaffold 
delivery systems. Another approach involves covalent tethering of genetic materials onto the 
nanoscaffolds, where subsequent release of genetic materials is triggered by a specific 
stimulus either internally or externally (Scheme 1). Plasmid DNA and siRNA are the two 
main categories of genetic material to be delivered to cells for gene therapy. siRNA is able to 
cause RNA interference (RNAi) and post-transcriptional gene silencing. This has sparked 
research interest in utilising RNAi for both biomedical research and therapeutic applications. 
Due to high negative charges, 'naked' plasmid DNA and siRNA cannot cross cellular 
membranes freely. Meanwhile, siRNA is easily digested by enzymes and DNase existing in 
the environment. Therefore, siRNA must be delivered under protection before reaching its 
destination and then be activated after delivery. The carriers must meet several requirements 
to be effective, including the ability to condense genetic materials into compact complexes 
that can be readily taken up by cells, efficient protection of genetic material from degradation 





Scheme 1. Fundamental steps of gene delivery by nanocarriers (orange spheres).  
 
Delivery and tracking 
Specific delivery and efficient release of genetic materials from their carriers are prerequisites 
for an effective therapy. Specific delivery / targeting could be achieved “actively” or 
“passively”.19, 20 “Active” targeting involves delivery of genetic materials aided either 
internally by the molecular-recognition-driven binding between a functional nanocarrier and 
the receptors on the membrane of a target cell, or externally by a magnetic gradient as in the 
case of magnetic nanoparticles. On the other hand, “passive” targeting relies on kinetically 
driven pre-concentration of genetic materials in unhealthy tissues by extravasation through 
the leaky blood vessels with 600 nm gaps. This type of enhanced permeation and retention 
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effect (EPR) favors loaded nanoscaffolds with a tailored size of around 5–10 nm to 
“passively” target on the unhealthy tissues.21 Nevertheless, non-specific uptake and potential 
degradation by macrophages can be problematic for systems relying only on the “passive” 
targeting method. Pun et al. recently reported the effects of various physicochemical 
parameters (size, PEGylation, and ligand type) on regulating non-specific versus target-
specific uptake.
22
 Release of genetic payload from the nanocarriers could similarly be 
triggered by internal (e.g. glutathione (GSH), or pH) or external (e.g. light) stimuli.
23-25
 
Notably, biochemical control can be achieved utilising the internal stimuli, whereas spatio-
temporal control can be done utilising external stimuli.  
 
There exist other factors that determine the effectiveness of gene therapy, including the 
coexistence of numerous gene mutations in many diseases and the short lifetime of 
therapeutic DNA within the dividing cells. On top of that, real-time non-invasive 
visualization of the delivery event was shown to be an important criterion in assessing the 
mechanism of a given gene therapy.
8
 Hence, there are an increasing number of delivery 
systems incorporated with various probes for monitoring the delivery process. Nanoscaffold 
delivery systems are advantageous in this aspect owing to their unique optical and/or 
magnetic properties allowing non-invasive and spatio-temporal molecular imaging of gene 
delivery. 
 
NANOPARTICLES FOR GENE DELIVERY 
In recent publications, inorganic nanoparticles such as, gold nanoparticles, iron oxide 
nanoparticles, and quantum dots, have been reported as alternative gene delivery vehicles. 
This was suggested on account of their unique intracellular behaviors with powerful cellular 
imaging capacities. The following sections will discuss various types of inorganic 
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nanoparticles and nanoscaffolds that have been suggested and the current stage of their 
research thus far.  
 
Gold nanoparticles (AuNPs) 
AuNPs have been popularly studied as multifunctional gene carriers due to their ease of 
synthesis, excellent biocompatibility, well-defined surface chemistry, and facile molecular 
imaging utilising fluorescence resonance energy transfer (FRET). A typical methodology for 
the preparation of AuNP-based gene delivery vectors is via surface functionalization of the 
nanoparticles with positively charged molecules such as amino acids, cationic peptides, and 
tertiary amine-containing molecules (Figure 1).
26, 27
 This creates a positively charged scaffold 
allowing the binding of DNA or siRNA for the formation of complexes which can then be 
taken up by the cells. Other methods include the exploitation of gold-thiol chemistry to 
conjugate genetic materials directly onto AuNPs as well as the layer-by-layer assembly of 
PEI and siRNA to form the gene nanocarriers. However, a major drawback of these methods 
is that the synthetic process requires multi-step surface functionalization and subsequent 
conjugation with cationic moieties. This produces a heterogeneous mixture of polyelectrolyte 
complexes which limits the effectiveness of these gene carriers. Recently, a new method to 
circumvent this effect was developed to prepare highly efficient and non-toxic AuNP gene 
carriers with controlled size and surface charge.
28
 In that work, controlled synthesis of 
polyethyleneimine (PEI)-coated AuNPs was achieved utilising catechol-conjugated PEI (PEI-
C) for siRNA delivery. The reductive catechol groups drive the formation of spherical multi-
cored micelles in aqueous solution and act as reductive templates for the growth of spherical 
AuNPs. Utilising these templates, AuNPs with tunable sizes and surface charges could be 
obtained. The PEI-coated AuNPs demonstrated low toxicity and an excellent gene silencing 





 AuNPs, combined with PEI were used to prepare two sets of PEI-coated Au 
NPs having particle-size distributions centered at about 6 nm (<10 nm Au-PEI NPs) or 70 nm 
(<100 nm Au-PEI NPs), respectively. Au-PEI NPs were coupled to a variety of plasmids 
carrying reporter or suicide genes to prepare Au-PEI NPs/DNA complexes. Human 
osteosarcoma Saos-2 cells were used to investigate the performance of the Au-PEI NPs as 
transfection vectors in serum-containing media. Cells were efficiently transfected with 
complexes derived from <10 nm Au-PEI NPs, but not with the <100 nm Au-PEI NPs. Large 
aggregates of NPs associated with DNA were found in endocytic vesicles of cells incubated 
with <100 nm Au-PEI NPs, while the success of the smaller Au-PEI NPs as transfection 





Figure 1. Gold nanoparticles (orange spheres) as multifunctional nanocarriers.  
 
The development of gold nanoparticles for gene delivery have greatly facilitated the 
development of mixed monolayer protected gold nanoparticles, complexes of polymer and 
gold nanoparticles, double-stranded DNA functionalized gold nanoparticles, and single 
stranded DNA functionalized gold nanoparticles.
30-34
 Single-stranded DNA functionalized 
gold nanoparticles developed by Mirkin et al. demonstrated excellent gene delivery 
efficiency.
31
 These nanoparticles demonstrated greater knockdown of gene expression, higher 
binding affinity for target DNA, higher immunity to nuclease, and lower cell toxicity than 
antisense DNA delivered by either Lipofectamine or Cytofectin. In another attempt to 
develop an effective gene delivery system for a material (e.g., oligo antisense DNAs specific 
to a target gene) which allows the inhibition of the expression of a target gene without 
affecting normal cell physiology, a gene delivery system was fabricated in which an universal 
binding partner is covalently linked to the surface of a nanomaterial followed by binding an 
inhibitory molecule having the sequence of the target gene of interest to be expressed as a 
binding counter-partner, contributing to inhibition or expression of the target gene in a more 
effective manner.
35
 In 2005, Japanese inventors created cationic gold nanoparticle or the 
polyethylene glycol (PEG)-modified cationic gold nanoparticles bearing a cationic 
cysteamine surface for gene delivery. The gold nanoparticle-nucleic acid complexes or the 
PEG-modified cationic gold nanoparticle-nucleic acid complexes, capable of delivering the 
nucleic acids to the interior of a cell or an in vivo tissue were produced by bonding the 
resultant gold nanoparticles to the nucleic acids. Interestingly, these complexes were 
internalized into the cells by the use of optical tweezers.
36
 In another approach, DNA loaded 
gold nanoparticles embedded in sharp carbonaceous carriers were used for efficient DNA 
delivery into plants. The “nanogold” embedded carbon matrices were prepared by heat 
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treatment of biogenic intracellular gold nanoparticles. The advantages of the composite 
carrier are the low plasmid and gold requirements. Plant cell damage utilising these gene 
delivery agents was minimal compared to that of the commercial micrometer sized gold 
particles. The efficient gene delivery can be attributed to the sharp edges that the carbon 
supports possess, which lead to better piercing capabilities with minimum damage.
37
 Gas-
phase self-assembly was used to synthesize biocompatible Au@PDMS–PLL soft 
nanocomposites which can be used for gene delivery and also photothermal therapy.
38
 Shan 
et al. reported a new gene delivery vector based on dendrimer-entrapped gold nanoparticles 
(Au DENPs) with significantly higher gene transfection efficiency than that of dendrimers 
without AuNPs entrapped due to the fact that the entrapment of AuNPs helps preserve the 3-
dimensional spherical morphology of dendrimers, allowing for more efficient interaction 
between dendrimers and DNA.
39
 Kong et al. recently reported the use of arginine-glycine-
aspartic (RGD) peptide-modified Au DENPs for highly efficient and specific gene delivery to 
stem cells.
40
 The native and the RGD-modified PEGylated dendrimers as well as the Au 
DENPs were used as vectors to transfect human mesenchymal stem cells with plasmid DNA 
(pDNA) possessing the enhanced GFP and the luciferase reporter genes, as well as pDNA 
encoding the human bone morphogenetic protein-2 (hBMP-2) gene. Xiao et al. reported Au 
DENPs modified with folic acid (FA) as a non-viral vectors for targeted gene delivery 
applications.
41
 Amine-terminated PAMAM dendrimers modified with FA via covalent 
conjugation were used as templates to synthesize gold nanoparticles. The delivery of pDNA 
into HeLa cells which has an overexpression of high-affinity FA receptors  was used to 
illustrate the targeting ability of the vectors. Au DENPs-FA vector enables much higher 
luciferase and EGFP gene expression in HeLa cells overexpressing FAR than the Au DENPs 
without FA, demonstrating the role played by FA-mediated targeting for enhanced gene 
transfection in target cells. An interesting study by Xu et al. studied the gene transfection of 
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polycation-functionalized Au NPs with five different morphologies (nanospheres, nano-
octahedra, arrow-headed nanorods, nanorods with different aspect ratios).
42
 The morphology 
of Au NPs is demonstrated to play an important role in gene transfection. The most efficient 
gene carriers are those fabricated with arrow-headed nanorods whereas nanospheres exhibited 
the poorest performance in gene transfection. The authors also found that nanorods with 
lower aspect ratios perform better than higher ones. Cationic polypeptide-gold 
nanoconjugates can also be synthesized by an environmentally benign one-pot synthesis 
approach, where polypeptides function as capping agents and as reductants for the formation 
of gold nanoparticles without the need of an additional reducing agent.
43
 The resulting 
positively charged polypeptide-conjugated gold nanoparticles are applied for gene delivery 
showing a gradual and prolonged intracellular uptake and transfection. Sustained transfection 
is maintained for almost two weeks with no obvious cytotoxicity.  
 
Figure 3. In vitro measurements of gene transfection efficiency of Au@PDMS–PLL 
nanocomposites including naked DNA, PEI, and SiO2@PLL reference samples. A 






The use of magnetic materials have been tried and tested in commercial biological 
applications such as diagnostics and biosensors.
44-50
 The crucial mediation and precise control 
of the interface between the inorganic phase of the material and the organic phase of the 
material are important considerations to success. Biomolecular recognition as well as 
biocompatibility can be tailored by modulating the organic phase, while physical properties 
such as magnetism can be elicited from the inorganic phase. Magnetic spherical particles 
which have dimensions extending down to the nanometer scale of 100 nm or less have been 
used for medical applications. Commercial magnetic nanoparticles (MNPs) are commercially 
available and have been exploited as gene delivery nanocarriers. Their small size allows 
MNPs to penetrate into cells. Ferrofluids made from magnetic ferrite nanoparticles are an 
important class of magnetic nanomaterial. Ferrofluids are extensively utilised in many 
applications such as audio speakers, smart seal magnetic circuits, and magnetic domain 
detectors. MNPs have also been suggested for different applications such as high-density 
magnetic data storage,
51, 52





biomedical applications such as magnetic carriers for bio-separation 
57, 58
 and enzyme and 
protein immobilization 
59
 and contrast-enhancing media.
60
 In addition, nanoparticles have 
been coated with a shell of stable and biocompatible material such as silica (SiO2) to avoid 




One of the uses of magnetic nanoparticles is in cell imaging. In recent examples, transmission 
electron microscopy (TEM) or magnetic resonance imaging (MRI) has been used to observe 
magnetic nanoparticles incorporated within cells. However, TEM and MRI are not 
convenient for in situ monitoring. Hence, a sensitive and easy technique for monitoring the 
nanoparticles in cells in situ is desirable. Confocal laser scanning microscopy (CLSM) is a 
highly sensitive detection technique specific to the fluorescence wavelength of the dye used. 
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Lee et al. described a well-controlled, versatile magnetic particle system which can be 
quantitatively analyzed and provides numerous advantages for commercial applications. In 
one embodiment, a magnetic motor effect was developed wherein magnetic particles 
entrapped inside of cells can be used to move the cells in a magnetic field. Gene delivery and 
specific targeting were also described and experimentally demonstrated.
63
 In another patent, 
Bikram reported the fabrication of magnetic biomimetic contrast agents which are dual 
functional: effective for therapeutic gene delivery and magnetic detection. These 
nanoparticles are made of functionalized iron oxide nanoparticle cores. The shell can be made 
of an inert gold layer, a layer of inert metal seeds or a silica layer. On top of that, the 
outermost corona is typically made of up of an outer gold-silver nanoshell and/or a targeting 
ligand attached to the inert metallic nanoshell. These materials can be used for in vivo 
magnetic resonance imaging, treating primary or metastatic cancers or ablating 
atherosclerotic plaque utilising the contrast agents and magnetic particles.
64
 Mykhaylyk et al. 
have described core–shell magnetic nanoparticles and their self-assembling complexes with 
viral and non-viral vectors. These nanoparticles were designed and comprehensively 
characterized based on their morphology, composition and magnetic properties. The 
protocols, developed with novel magnetic vectors, improve significantly nucleic acid delivery 
with adeno- and lentivirus vectors and are efficient to transfect primary cells, which are 
difficult to be transfected.
65
 In another method, a non-viral nanoparticle gene carrier was 
developed for siRNA delivery and transfection. The gene delivery vehicle was constructed 
with a core of iron oxide nanoparticles (IOs) and a shell of alkylated polyethyleneimine of 
2000 kDa molecular weight. The knockdown efficiency of the siRNA-loaded nanocarriers 
was assessed with 4T1 cells stably expressing luciferase (fluc-4T1) and further, with a fluc-
4T1 xenograft model. Significant down-regulation of luciferase was observed, and unlike 





Magnetic nanoparticles can be used to enhance gene transfection of viral vectors and non-
viral vectors. In such systems, the genetic material is attached to magnetic nanoparticles and 
the delivery to the targeted cells are accomplished through the use of high-field/high-gradient 
magnets. The transfection efficiency of this technique is comparable to commercially 
available gene transfection agents such as Lipofectamine. The improvement of the overall 
transfection levels was achieved by using an oscillating magnet array system with results 
showing an enhancement of the in vitro transfection levels in human airway epithelial cells 
compared to static field techniques and Lipofectamine tested.
67
 Fouriki et al. investigated the 
effects of a novel nonviral oscillating magnet array system in enhancing transfection 
efficiency of primary human mesenchymal stem cells (hMSCs).
68
 Plasmids encoding for GFP 
were coupled to magnetic nanoparticles (MNPs) and introduced to hMSCs in culture. 
Magnetic fields generated by magnets positioned below the culture plates direct the 
MNP/DNA complexes to the cells. The oscillation of the magnetic arrays promoted more 
efficient endocytosis via mechanical stimulation. This improved transfection efficiency as 
well as cell viability, additionally; the expression of hMSC-specific cell surface markers was 
unaffected. This technique was also useful for enhancing the transfection of plasmids to 
NIH3T3 mouse embryonic fibroblasts, MG-63 osteoblasts and adult cardiomyocytes.
69-71
 
Carbon nanotubes (CNTs) 
CNTs have been widely explored for potential biomedical applications since the first 
publication of CNT in 1991.
72-76
 CNTs are one dimensional tubes of rolled-up graphene 
layers, with a length ranging from hundreds of nanometers up to tens of microns. Single-
walled carbon nanotubes (SWNTs) are composed of a single graphene sheet with a diameter 
as small as 0.4 nm. Multi-walled carbon nanotubes (MWNTs) are made up of multiple 
concentric SWNTs with a diameter of about 100 nm. Biomolecules, imaging agents and 
drugs can be routinely tethered onto the surface of the CNTs via well documented 
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functionalization procedures. Functionalization of CNT surface can be typically done by (1) 
oxidation of the CNTs in acidic conditions and 1,3-dipolar cycloaddition reaction, yielding a 
covalently linked functionality or (2) hydrophobic or π-π stacking between the CNTs and 
another non-polar ring such as the backbone of DNA to produce non-covalent conjugates. 
The resultant water-soluble CNT constructs can subsequently be used for gene delivery 
purposes. Essentially ammonium-functionalized CNTs can bind plasmid DNA by 
electrostatic attractions. The entire bioconjugate can then penetrate the cell membrane 
through a nano-needle model as visualized by TEM (Figure 2).
77
 Notably, CNTs are 
considered as exceptional nanomaterials for gene and drug delivery, as they offer an uptake 
pathway independent of endocytosis of mammalian cells. Both SWNTs and MWNTs have 
also been found to form stable complexes with plasmid DNA and allow for the successful 
delivery of genes.
78, 79
 Moreover, fluorescent markers and biomolecules have been attached to 
the CNT walls for studying the cellular uptake efficiency. In particular, CNTs were 
covalently linked with fluorescein or biotin to form a fluorescent biotin-avidin complex in a 






Figure 2. Direct injection and release of quantum dots (QD, green spheres) as mediated by a 
multi-walled carbon nanotube (MWNT) attached on an AFM tip.  
 
Graphene 
Graphene/CNT composites were used for gene transfection of pIRES plasmid conjugated 
with green fluorescent protein (GFP) in NIH-3T3 and NG97 cell lines.
81
 Oxygen groups were 
attached on the MWCNT surfaces by plasma treatment. The composites and pIRES plasmid 
conjugated with the GFP gene were physically mixed and used for gene transfection with low 
cytotoxicity and good transfection efficiency. Surface-initiated ATRP of (2-dimethyl 
amino)ethyl methacrylate (DMAEMA) was used to tailor the GO surfaces in a well-
controlled manner, producing a series of organic inorganic hybrids (termed as SS-GPDs) for 
highly efficient gene delivery. Under reducible conditions, the PDMAEMA side chains can 
be readily cleavable from the GO backbones, benefiting the resultant gene delivery process. 
Moreover, due to the conjugated structure of the graphene basal plane, SS-GPD can attach 
and absorb aromatic, water insoluble drugs, such as 10-hydroxycamptothecin (CPT), 
producing SS-GPD-CPT. The MU assay and the simultaneous double-staining procedure 
revealed that SS-GPD-CPT possessed a high potency of killing cancer cells in vitro. Chitosan 
was covalently conjugated to graphene oxide through an amidation process.
82
 The chitosan-
grafted GO sheets possess good aqueous solubility and biocompatibility. The chitosan-
grafted GO sheets could condense plasmid DNA into stable, nanosized complexes, and the 
polyplexes exhibited reasonable transfection efficiency to cells. In another system, GO was 
bound with PEI with two different molecular weights (1.2 kDa and 10 kDa).
83
 It appears that 
GO conjugated with PEI-10k complex shows greatly reduced toxicity to the treated cells 
compared to the pristine polymer. A demonstration of intracellular transfection of the 
enhanced green fluorescence protein (EGFP) gene in HeLa cells was successful. Interestingly, 
EGFP transfection with PEI-1.2k was ineffective, but high EGFP expression was observed 
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using the corresponding GO-PEI-1.2k as the transfection agent. GO-PEI-10k shows similar 
EGFP transfection efficiency but possessed lower toxicity compared with PEI-10k. A similar 
system studied by Kim et al. also showed that the incorporation of GO improved DNA 
binding and condensation/transfection efficiency.
84
 Additionally, the modified GO was used 
for sensing and bioimaging as it possessed tunable and inherent electrical and optical 
properties. The authors also showed high transfection efficiency comparable to that of high-
molecular weight BPEI, it was also non-toxic and could be extended to siRNA delivery and 
potentially photothermal therapy. This was further investigated by the same group in the 
development of an externally stimuli-triggered spatially and temporally controlled gene 
delivery system.
85
 A photothermally controlled gene delivery carrier, synthesized by linking a 
low molecular-weight BPEI and reduced GO (rGO) through a hydrophilic PEG spacer. The 
hybrid system forms a stable nano-sized complex with plasmid DNA (pDNA) and showed 
better gene transfection efficiency without significant toxicity compared to unmodified 
controls in PC-3 and NIH/3T3 cells. NIR irradiation led to accelerated endosomal escape of 
polyplexes augmented by locally induced heating of the hybrid system leading to an 
enhancement of the gene transfection. Chen et al. also showed that this GO-PEI system 
shows excellent condensation of DNA at a low N/P ratio.
86
 The PEI-GO is also greatly less 
cytotoxic than PEI 25 kDa. The transfection efficiency of PEI-GO was also higher than that 
of the PEI 25 kDa at optimal mass ratio. Graphene functionalized with oleate-
polyamidoamine (PAMAM) dendrimers hybrids were examined for its gene transfection 
efficiency.
87
 The PAMAM dendrimers were densely tethered onto the graphene surface and 
showed good dispersity and aqueous stability. The hybrid materials did not show significant 
toxicity to HeLa and MG-63 cells. The delivery of plasmid DNA encoding for GFP was used 
as an indicator of gene transfection capability of the hybrids. Interestingly, the ultrasonicated 
graphene shows some gene transfection ability and the surface modification of graphene with 
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oleic acid/PAMAM further improves the gene transfection efficiency by 13 times. Patterned 
GO substrates were fabricated for gene transfection using an imprinting approach by 
mechanical pressure (Figure 3).
88
 This methodology does not require additional chemical 
reagents and is straightforward and robust. PEI/pDNA complexes were selectively 
preconcentrated on GO designs, and can be made to release in a sustainable manner. The 
patterned GO substrates exhibit excellent biocompatibilities and deliver genes encoding for 
GFP efficiently in a localized manner showing clear boundaries with groups of cells cultured 
on adjacent areas of the glass. The toxicity of the graphene has been a subject of intense study 
as well. This is covered in depth in a recent review.
89
 Graphene appears not to have much 
toxicity against selected bacteria and a mild cytotoxic action on Caco-2 cells after 24 h of 
exposure.
90
 The theoretical evaluation of the toxicity of graphene can be investigated with 
large-scale all-atom molecular dynamics simulations.
91
 It appears that the hydrophobic 
protein-protein interaction critical to biological functions are interrupted by the insertion of a 
graphene nanosheet, as it is energetically favorable for a graphene nanosheet to enter the 
hydrophobic interface of two contacting proteins, such as a dimer. It has been hypothesized 
that the forced separation of two functional proteins can disrupt the cells metabolism thus 
leading to cells mortality. The size of the graphene particles also appears to have an effect.
92
 
The increased toxicity of smaller graphene nanoflakes (30 nm vs 80 nm) as measured by 
electrochemical impedance sensing and optical monitoring of treated cells was observed by 
Yoon et al. The size effect was further probed in another study. Chong et al. further showed 
that graphene quantum dots (size ~3-5 nm) exhibit very low cytotoxicity which was 
attributed to its ultra-small size and high oxygen content.
93
 In vivo studies revealed no 
material accumulation in the main organs of mice as well as fast clearance of graphene 
quantum dots through the kidney. However, it is critical to note that when mice were injected 
with graphene quantum dots and GO (size ~10–30 μm, as comparison) multiple times for in 
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vivo toxicity tests, GO appeared toxic causing death in mice due to GO aggregation whereas 
the quantum dots showed no obvious influence on mice, even under multi-dosing situations. 
 
Figure 3. (a) Schematic illustration of preparing patterned GO substrates and the subsequent 
reverse gene transfection in cells. (b) Optical micrograph showing a panel of patterned GO 
substrates. (c) SEM image of GO substrates, black arrows indicating the wrinkles on the 
surface of GO. (d) Raman spectrum of GO substrates. (e) Contact angle of GO substrate, 
compared with glass and tissue culture plate. 
 
Quantum dots (QDs) 
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Utilising QDs as siRNA carriers is one of the efficient methods to achieve this purpose 
because QDs is luminous and can be used as fluorescence probes for living cells, in vivo 
cancer targeting and diagnostics.
94-98
 Although the cytotoxicity of QDs limited its biological 
applications, this problem has been improved by organic-hydride modification. Quantum dot 
(QDs) can be used as bioimaging agents and delivery vehicles for gene therapeutics in cells. 
Yang et al. designed multiple QD bundled nanoparticles (NPs) to investigate the effect of QD 
size and poly(ethylenimine) (PEI) coating on the efficiency of gene delivery into human 
mesenchymal stem cells (hMSCs).
99
 Gene-complexed QD bundled NPs could be detected in 
the hMSCs using several different methods such as fluorescence-activated cell sorter, 
confocal laser scanning microscopy, and in vivo optical imaging. Particularly, the largest QD 
bundled NPs examined, 20 nm QDs, had a much higher uptake capability and greater gene 
expression ability than the other QD NPs (15 nm > 10 nm > 5 nm). Antibacterial fluorescent 
carbon dots have also been reported for gene transfection applications.
100
 Derfus et al. 
described the conjugation of siRNA and tumour targeting peptides on the surface of a 
PEGlyated quantum dot core as a scaffold (Figure 4). The targeting peptide was required for 
targeted internalization by tumor cells. Utilising an enhanced green fluorescent protein 
(EGFP) model system, the role of conjugation chemistry was investigated, with siRNA 
attached to the particle by disulfide cross-linkers showing greater silencing efficiency than 
when attached by a non-reducible thioether linkage. Delivery of these peptide/siRNA−QDs to 
EGFP-transfected HeLa cells and release from their endosomal entrapment led to significant 
knockdown of EGFP signal. The authors suggested designing the siRNA sequence against a 
therapeutic target (e.g., oncogene) instead of EGFP, and utilising this technology to 






Figure 4. Multifunctional quantum dots for siRNA delivery.  
Li et al. demonstrated in his paper that water-soluble and cysteamine protected CdTe QDs, 
which were positively charged in neutral condition, formed larger complexes with plasmid 
DNA through simple electrostatic attractions. The transcriptional activity of DNA was 
inhibited by the formation of the QDs-DNA complexes. When GSH was added at 
intracellular concentrations, the entrapped DNA was released and recovered the ability to 
express the reporter protein in HEK 293 cells. The strong association and burst release 
mediated by GSH at intracellular concentrations without obviously injuring the 
transcriptional viability of DNA implied that this positively charged QDs had the potential to 
be used as a new visible vehicle for gene or drug delivery.
102
 Li et al. demonstrated the 
design of functional quantum dots to overcome barriers in siRNA delivery such as siRNA 
protection, cellular penetration, endosomal release, carrier unpacking, intracellular transport 
and gene silencing. In that paper, two L-arginine-functional-modiﬁed CdSe/ZnSe QDs were 
synthesized as siRNA carriers to silence HPV18 E6 gene in HeLa cells. The QDs coated with 
β-CD-l-Arg (where CD = cyclodextrin) demonstrated optimized property compared with 
those coated only with l-Arg. Furthermore, these QDs complexes could also be used as 
nanocrystal probing agents, allowing real-time tracking and localization of QDs during 
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delivery and transfection. The properties and capabilities of these QDs demonstrated that 
amino acid-modiﬁed QDs could be used as useful siRNA carriers to efficiently silence a 
target gene as well as fluorescence probes to analyze intracellular imaging in vivo.
103
 Zhao et 
al. reported a new class of multifunctional nanoparticles for siRNA delivery. The carboxyl 
groups in the β-CD coupled to amino acid ligands were used as the anchoring groups to 
replace the organic alkylamine ligands-coated on CdSe/ZnSe core-shell nanocrystals, as well 
as the anchoring groups to link other functional molecules. The β-CD coupled to amino acids 
improved the solubility and stability of the coated QDs in cell culture media, kept the long 
fluorescence lifetime, and reduced cellular toxicity. These nanoparticles were used to 
examine the cellular uptake and intracellular transport of QDs in living cells. Compared with 
current siRNA delivery reagents, such as siPort NeoFX, and HiPerFect, the gene-silencing 
activity of the QDs was slightly improved for HPV18 E6 gene in HeLa cells. In addition, the 
QDs should also provide a bright and stable fluorescent signal for intracellular siRNA 
imaging.
104
 Amphiphilic polyethyleneimine derivatives (amPEIs) were synthesized and used 
for the encapsulation of QDs.
105
 These particles showed very efficient QD cellular labeling 
with the labeled cell fluorescence intensity more than 10 times higher than conventional 
techniques such as Lipofectamine-assisted QD delivery. This material could be used for a 
combination of gene delivery, cell-specific labeling, and ratiometric oxygen sensing. Co-
delivery of QDs and GFP silencing RNAs was successfully demonstrated by assembling 
siRNAs to the outer surfaces, which showed the transfection efficiency an order of magnitude 
higher than conventional gene transfections. Specific gene transfection can be achieved by 
conjugating hyaluronic acids onto the QD-amPEI for cell-specific targeted labeling showing 
the specific-to-nonspecific signal ratio over 100. Shao et al. combined an HSV-TK/GCV 
suicide gene system and near-infrared quantum dots for liver cancer treatment and 
simultaneous tumor imaging.
106
 A targeting capability was added by developing a folate-
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modified theranostic liposome (FL/QD-TK) comprising an HSV-TK suicide gene covalently 
coupled to CdSeTe/ZnS core/shell QDs. FL/QD-TK exhibited highly specific tumor imaging 
and strong inhibition of the folate receptor-overexpressed Bel-7402 mouse xenografts without 
systematic toxicity. Conjugating ligands with nanoparticle-based carriers for specific delivery 
of therapeutic nucleic acids (such as antisense oligonucleotides and siRNA) to tumor sites is 
promising for the treatment of cancers. Inherent weaknesses such as a lack of selectivity and 
poor transfection efficiency have limited applications. Zhang et al. designed a dual receptor-
targeted QDs gene carrier QD-(AS-ODN+GE11+c(RGDfK)) with increased cellular uptake 
efficiency and enhancement in transfection efficiency.
107
 In this case, peptides GE11 and 
c(RGDfK) which could recognize epidermal growth factor receptors (EGFR) and integrin 
alpha v beta 3 receptors were conjugated to the nanoparticles, respectively. Synergistic effect 
between EGFR and integrin ανβ3 enhanced the cellular uptake of QDs carriers. The effects of 
inhibition agents showed the endocytosis pathway of QD-(AS-ODN+GE11+c(RGDfK)) 
probe was mainly clathrin-mediated. This dual receptor-targeted gene carrier achieved 
desired transfection efficiency.  
Upconversion nanoparticles (UCNs) 
Various means have been attempted for gene activation upon delivery. Among them, 
controlling by light has gained popularity in the past decade. Lanthanide-doped photo-UCNs 
possess unique optical and chemical properties. UCNs emit high-energy visible light by 
absorbing several near-infrared (NIR) photons.
108
 The special features allow them to 
overcome various problems associated UV responsive gene deliveries with similar efficacy 
but with deeper penetration for gene activation. UCNs have gained enormous attention for 
photo-controllable gene delivery and have been employed to deliver nucleic acids in gene 
therapy. In this section, several approaches will be discussed to utilize UCNs based gene 
delivery vectors for traceable gene delivery and therapy. Zhang’s group pioneered the 
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research of employing UCNs as gene vectors. In 2009, Zhang's group reported the delivery of 
siRNA to SK-BR-3 cancer cells with anti-Her2 antibody bonded NaYF4 UCNs.
109
 GL3 
siRNA was firstly attached to anti-Her2 antibody and then anti-Her2 antibody conjugated to 
silica-coated UCNs. The effect of siRNA on gene silencing was confirmed by a luciferase 
assay. Further work by the group led to the development of another method to monitor the 
delivery and release of siRNA into live cells via fluorescence resonance energy transfer 
(FRET) between BOBO-3-stained siRNA and UCNs.
110
 BOBO-3-siRNAs were attached to 
the surface of amino-group-modified silica/NaYF4:Yb,Er UCNs. Subsequently, the 
intracellular release and biostability of siRNA in live cells was investigated via FRET 
between UCNs and BOBO3, where UCNs as the donor and the siRNA-intercalating dye 
BOBO-3 as the acceptor (Figure 5). Once the siRNA was detached from UCNs, the FRET 
process was inhibited. siRNA release in cells sustained for 24 h, which was observed by 






Figure 5. Synthesisof the UCN/siRNA-BOBO3complex. (A)TEM image of 
silica/NaYF4:Yb,Er upconversion nanoparticles. (B) Schematic drawing of FRET-based 
UCN/siRNA-BOBO3 complex system. siRNA are stained with BOBO-3 dyes, and the 
stained siRNA are attached to the surface of NaYF4:Yb,Er nanoparticles. Upon excitation of 
the nanoparticles at 980 nm, energy is transferred from the donor (UCN) to the acceptor 
(BOBO-3). (C) Fluorescence spectra of the UCN and siRNA-BOBO3. The spectra are 
normalized to the same intensity level. (D) Fluorescence spectra of freeUCN solution and 
UCN/siRNA-BOBO3 complex solution. (E) Gel eletrophoresis image of siRNA. Lane 1, 
DNA ladder; lane 2, siRNA control; lane 3, free siRNA in the supernatant of UCN/siRNA-
BOBO3 complex. Reproduced from 
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Similarly, the group continued to report the approach to utilize FRET for gene delivery with 
UCNs.
111
 In this approach, POPO-3 dye intercalating the green fluorescent protein (GFP)-
encoded plasmid DNA was carried by amino-functionalized silica-coated β-NaYF4:Yb, Er 
UCNs (Figure 6). FRET between POPO-3 and UCNs was checked with confocal microscopy 
to track DNA attachment or release. They were able to achieve successful in vitro and in vivo 
delivery of DNA, which were confirmed by expression of its encoded GFP in Hela cells 24 h 
post-transfection and induction of the antibody against the expressed encoded GFP in 
immunocompetent mice, respectively.  
 
Figure 6. Schematic drawing of LRET occurring between the nanoparticle donor and POPO-




Recently, Zhang's group reported the use of UCNs (composed with NaYF4: Yb, Tm) for 





 UCNs acted as nanotransducers to absorb NIR light having high tissue penetration 
power to emit UV light locally. Plasmid DNA encoding GFP and siRNA targeting GFP 
mRNA were both caged with 4,5-dimethoxy-2-nitroacetophenone (DMNPE) to block their 
respective functions. UCNs coated with mesoporous silica were used to carry the caged RNA. 
Upon NIR light, they were activated by the energy transferred from UCNs, inducing 
controlled gene expression and subsequently specific gene silencing. Cells transfected with 
UCNs containing photocaged GFP plasmid were loaded into a polydimethylsiloxane (PDMS) 
device, which was transplanted into mice. Efficient activation was observed for the cells in 




Figure 7. (A) Plasmid DNA and siRNA are caged with DMNPE and then uncaged by 
upconverted UV light from NIR-to-UV UCNs. Inset shows the penetration depth of UV and 




In a later work, Liu and Xing et. al reported a NIR light-induced siRNA release system with 
silica coated UCNs (Si-UCNs).
113
 siRNA was loaded to the Si-UCNs carrier by electrostatic 
force to cationic photocaged linkers covalently linked on Si-UCNs (Figure 8). The system 
could easily internalized by living cells. Upon NIR light irradiation, the photocaged linker 
was cleaved off from UCNs by the upconverted UV light, which initiated the intracellular 
release of the siRNA. The in vitro agarose gel electrophoresis and intracellular imaging 
results indicated that the Si-UCN-based gene carrier system allowed effective siRNA 




Figure 8. Schematic illustration of (A) the synthesis processes of cationic photocaged Si-
UCNPs; (B) siRNA adsorption on the particles surface and then photo-release by 
upconverted UV light from UCNPs. Reproduced from 
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Li, Guo and Liu reported UCN-PEG@2×PEI complex for delivery of plasmid DNA (pDNA) 
encoding enhanced green fluorescent protein (Figure 9).
114
 NaGdF4-based UCNs was first 
modified with poly(ethylene glycol) (PEG) and then with two layers of poly(ethylenimine) 
(PEI) via covalent conjugation and layer-by- layer assembly, respectively. They found two 
layer of PEI modification of UCNs showed superior gene transfection efficiency compared to 
one layer PEI modification in both serum-free media, but slightly less effective than free PEI 
polymers. In serum-containing media, UCN-PEG@2×PEI showed remarkably enhanced 
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transfection efficiency. Gene delivery could be tracked by both upconversion luminescence 
and magnetic resonance imaging contrasting ability of UCNs. 
 
Figure 9. (a) Schematic illustration showing the synthesis of UCN-PEG@2×PEI gene vector 
and the subsequent pDNA binding. (b) Scheme showing proposed mechanism of serum-
enhanced gene transfection with our UCN vectors. Reproduced from 
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Similarly, Lin et al. also reported cationic polymer coated UCNs@PEI for gene transfection 
(Figure 10).
115
 In vitro studies revealed that transfection efficiency of EGFP plasmid DNA 
into Hela cells with UCNs@PEI were higher than PEI. Gene silencing was significant as 




Figure 10. UCNs@PEI for gene delivery and MRI/CT/UCL trimodality imaging. 
Very recently, Wang et al. reported polymer coated UCNs for gene delivery. They firstly 
synthesized positively charged amphiphilic polymer (MFAP) with polysuccinimide (PSI), N-
(3-aminopropyl) imidazole (NAPI) and oleylamine (OAm).
116
 Then NaYF4:Yb/Er UCNs 
were coated with MFAP together with PEG-PLGA, endowing the hydrophilic 
UCNPs@MFAP nanocapsules with positive charge surface and water dispersibility (Figure 
11). Negatively charged pDNA was absorbed on UCNPs@MFAP by electrostatic interaction. 





Figure 11. Schematic illustration for the synthesis of amphiphilic polymer (MFAP) (A) and 
the fabrication of gene nanocapsules, real-time luminescence tracking of gene delivery and 
monitoring transfection efficiency (B) made it easier to form a uniform and stable composite 
nanovector. Reproduced from 
116
 
The above cases showed the possibility of delivering genetic materials with UCNs and to 
achieve controlled release. To summarize, there are mainly two methods for the UCNs to host 
the genes as a vector: 1) loading genes in mesoporous silica coated on the UCN surface, 2) 
Genes are absorbed on positively charged polymer/antibody coated on UCN via electrostatic 
force. This technique brings the light controlled gene delivery/knockdown to a deeper level in 
the tissue using safe NIR light, which adds advantages to gene therapy. 
Silica nanoparticles 
Mesoporous silica nanoparticle (MSN) is a promising material for biomedical applications, 
such as delivering drugs or biological molecules (siRNA or DNA) to the target cells or 
tissues. This is because of focal points, for example, accessibility in permeable structures for 
encapsulation of medications and genes, extensive surface region to stack biomacromolecules, 
biocompatibility, material stability, and simple synthesis at cost efficient rates. With positive-
charge functionalization on their surface, MSNs are suitable as vectors for siRNA delivery. 
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MSNs with small pore size (~3 nm) have been utilized for plasmid delivery. Xia et al. 
reported the use of MSNs modified with PEI to adsorb negatively charged plasmid DNA onto 
the surface for loading and cellular delivery.
117
 Others used cationic materials such as 
dendrimers 
118
 and cationic lipids 
119
 for surface modification. Modification of the surface 
with cationic components was necessary for DNA adsorption.
120-122
 However, the mixing of 
the genetic material with the MSNs does not fully utilize the mesopores and prevents further 
modifications on the particle surface. Furthermore, DNAs that are conjugated or adsorbed 
onto a nanoparticle surface can be easily degraded by nucleases. Therefore, it would be ideal 
if DNAs are packaged into a protective space for protection against degradation until they are 
released inside cells. Utilising a strongly dehydrated solution condition, Li et al. have 
successfully packaged siRNA into the mesopores of magnetic mesoporous silica 
nanoparticles (M-MSNs). The siRNA-loaded M-MSNs were mixed with PEI to form a 
polymer layer on their external surface. This method protects the siRNA efficiently and 
shows negligible cytotoxicity. In gene silencing experiments, these delivery vehicles 
mediated, with high efficiency, knockdown of both exogenous enhanced green fluorescent 
protein gene and endogenous B-cell lymphoma 2 (Bcl-2) gene. Kim et al. presented a report 
on the synthesis of MSNs having very big pores (>15 nm) and use of the nanoparticles for 
plasmid DNA delivery to human cells.
123
 The aminated MSNs with big pores allowed a 
greater loading capacity for plasmids than those with small pores of about 2 nm. The complex 
of M-MSN with plasmid DNA readily entered into cells without supporting polymers such as 
cationic dendrimers. Furthermore, M-MSN with big pores could competently protect 
plasmids from nuclease-mediated hydrolysis and demonstrated higher transfection efficiency 
of the plasmids encoding luciferase and green fluorescent protein (pLuc, pGFP) compared to 




Conclusion and Outlook 
At present, the examination of inorganic nanoparticles for good gene delivery is at a 
developmental stage and one could expect that numerous specialists would be laying cases to 
their developments. Prior to making a choice on the kind of nanoparticle for good gene 
delivery applications, a few inquiries must be tended to: What is the quality transfection 
proficiency? What happens to the nanoparticles after utilization? Are these nanoparticles 
good for utilization in the body? From these contemplations, research into inorganic 
nanoparticles for good gene delivery can be visualized to develop in the accompanying areas: 
i) advancement of novel nanomaterials for good gene delivery; ii) key structure–property 
relationship examination on cytotoxicity and transfection productivity; iii) lifetime studies; 
and iv) in vivo practical studies. The examination of vectors for good gene delivery is a wide 
field of study. It is impossible that any one material will satisfy the necessities of all the 
diverse applications. Consequently, new materials or mixes of materials must be produced for 
particular applications. The natural connections between the material and the body are 
essential variables to consider when utilizing these nanoparticles as a part of the body. For 
instance, functionalization of the nanoparticle with cell-binding segments could enhance the 
connection of the molecule to the objective cells, driving the way towards focused on 
targeted delivery. The steadiness of the nanoparticle ought to be evaluated in sensible 
profundity. This will permit specialists in this field to have a complete comprehension of the 
lifetime of the item, the action of different filtering systems in the body and the way of the 
metabolized and excreted fragments are treated. To date, there are just restricted studies 
completed to answer these inquiries and more work must be done here. In vivo tests can be 
completed to examine the flow component and extreme destiny of the nanoparticles in the 
body and additionally the gene delivery efficiency. This field bears huge useful potential, 
especially for malignancy medicines and hereditary revision treatment. The combination of 
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nanoparticles with soft materials such as hydrogels could potentially drive the area of gene 
delivery forward. This is able to endow the clinicians seeking gene therapy with new tools 
such as transfection, imaging, sustained delivery and facile administration in one system.
124-
127
 The interdisciplinary advancement of these nanoparticles will bring material researchers, 
scientists, scientific expert and clinicians together in an exploration setting with the regular 
objective of driving us closer to the day when people will profit by the utilizations of these 
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